Nektar Launches Phase 1 Trial Testing NKTR-255 in Non-Hodgkin’s Lymphoma, Multiple Myeloma
News
Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial assessing the safety and efficacy of its investigational agent NKTR-255 in people with relapsed or refractory non-Hodgkin’s lymphoma and multiple ... Read more